DA Davidson Forecasts Strong Price Appreciation for CVS Health (NYSE:CVS) Stock

CVS Health (NYSE:CVS) had its price target boosted by investment analysts at DA Davidson from $80.00 to $100.00 in a report issued on Thursday,MarketScreener reports. The firm presently has a “buy” rating on the pharmacy operator’s stock. DA Davidson’s price objective indicates a potential upside of 10.50% from the stock’s current price.

A number of other analysts have also recently issued reports on CVS. HSBC increased their target price on CVS Health from $83.00 to $85.00 and gave the stock a “hold” rating in a research note on Tuesday. Argus lowered their price objective on shares of CVS Health from $91.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, January 28th. Leerink Partners restated an “outperform” rating and set a $98.00 price objective on shares of CVS Health in a report on Thursday, March 5th. Bank of America cut their price objective on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating on the stock in a research report on Tuesday, January 27th. Finally, Sanford C. Bernstein upgraded CVS Health from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $91.00 to $94.00 in a report on Thursday, March 12th. Twenty-two analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $95.92.

CVS Health Stock Performance

Shares of CVS Health stock opened at $90.50 on Thursday. The stock’s fifty day simple moving average is $76.86 and its 200 day simple moving average is $78.03. The company has a current ratio of 0.87, a quick ratio of 0.63 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $115.47 billion, a PE ratio of 39.87, a PEG ratio of 0.88 and a beta of 0.60. CVS Health has a 12 month low of $58.35 and a 12 month high of $90.89.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.36. The company had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, research analysts predict that CVS Health will post 7.43 EPS for the current year.

Hedge Funds Weigh In On CVS Health

A number of large investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd increased its position in shares of CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares during the last quarter. Swiss RE Ltd. acquired a new position in CVS Health during the fourth quarter valued at approximately $26,000. Sankala Group LLC bought a new position in CVS Health in the fourth quarter valued at approximately $28,000. Global Trust Asset Management LLC increased its position in shares of CVS Health by 344.8% during the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock worth $28,000 after purchasing an additional 300 shares during the last quarter. Finally, Mcguire Capital Advisors Inc. bought a new stake in shares of CVS Health during the 4th quarter worth approximately $28,000. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS beat Wall Street expectations on Q1 earnings and revenue, reporting about $2.9 billion in profit, with improved Aetna profitability helping drive the upside. The company also raised its 2026 outlook, which investors are reading as a sign that the turnaround is gaining traction. CVS Raises 2026 Outlook As Shares Jump 9.8%
• Positive Sentiment: Several brokerages lifted price targets on CVS, including UBS to $100, Truist to $102, and Deutsche Bank to $92, reinforcing the view that recent operating improvements could support more upside from here.
• Positive Sentiment: Analysts and media reports highlighted improving Medicare Advantage metrics, better medical benefit ratios, and operational efficiencies, suggesting CVS’s health insurance business is moving back toward its longer-term margin targets.
• Positive Sentiment: Commentary from investors and media noted that CVS’s prescription volume and pharmacy operations remain solid, while biosimilar and AI initiatives may support long-term cost control and affordability efforts.
• Neutral Sentiment: Pieces discussing Jim Cramer’s prior favorable view on CVS and articles questioning whether the stock is still attractive mainly reinforce sentiment around the name, but do not add new fundamental information.
• Negative Sentiment: Some articles pointed to ongoing structural pressure in the PBM business and the risk that temporary insurance profit strength may not fully offset longer-term margin challenges.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.